Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESBA1008 versus Lucentis for wet age-related macular degeneration
NL-OMON35753Active, not recruiting
- Sponsor
- Alcon Inc.
- Start
- Oct 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of brolucizumab and ranibizumab in age-related macular degeneration (AMD) (2 arms), sponsored by Alcon Inc. Primary endpoint: Safety endpoints. Started Oct 2011; status: active, not recruiting.
02
Drugs
brolucizumabranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON35753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35753.